Review of dialysate calcium concentration in hemodialysis

Hemodialysis International

Volumn 10, Issue 4, 2006, Pages 326-337

  Toussaint, Nigel ^a   Cooney, Patrick ^a   Kerr, Peter G ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

Calcium phosphate product; Calcium balance; Dialysate calcium; Hemodialysis; Mineral metabolism; Vascular calcification

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; ALUMINUM HYDROXIDE; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CINACALCET; DOXERCALCIFEROL; LANTHANUM CARBONATE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D; VITAMIN D DERIVATIVE;

ARTICLE; BONE TURNOVER; BRAIN DISEASE; CALCIFICATION; CALCIUM BALANCE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIALYSATE LEVEL; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; HEART ARRHYTHMIA; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOTENSION; KIDNEY FAILURE; MEDICAL EDUCATION; OSTEOMALACIA; PHOSPHATE BALANCE; RENAL OSTEODYSTROPHY; RISK REDUCTION; SECONDARY HYPERPARATHYROIDISM; VITAMIN SUPPLEMENTATION;

BLOOD PRESSURE; BONE DISEASES; CALCINOSIS; CALCIUM; CARDIOVASCULAR DISEASES; EDUCATION, MEDICAL, GRADUATE; HEMODIALYSIS SOLUTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; LANTHANUM; POLYAMINES; RENAL DIALYSIS; VASCULAR RESISTANCE; VICTORIA; VITAMIN D;

EID: 33749355680     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2006.00125.x     Document Type: Article

References (78)

1. Palmer B. Individualizing the dialysate in the hemodialysis patient. Semin Dial. 2001; 14: 41-49.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42 (Suppl 3): S1-S202.
3. Johnson WJ, Goldsmith RS, Beabout JW, Jowsey J, Kelly PJ, Arnaud CD. Prevention and reversal of progressive secondary hyperparathyroidism in patients maintained by hemodialysis. Am J Med. 1974; 56: 827-832.
4. Slatopolsky E, Weerts C, Lopez-Hilker S, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med. 1986; 315: 157.
5. Slatopolsky E, Weerts C, Norwood K, et al. Long term effects of calcium carbonate and 2.5mEq/L calcium dialysate on mineral metabolism. Kidney Int. 1989; 36: 897.
6. Sawyer N, Noonan K, Altmann P, Marsh F, Cunningham J. High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: Effective phosphate control and aluminium avoidance in hemodialysis patients. Nephrol Dial Transplant. 1989; 4: 105-109.
7. Van der Merwe W, Rodger R, Grant A, et al. Low calcium dialysate and high-dose oral calcitriol in the treatment of secondary hyperparathyroidism in hemodialysis patients. Nephrol Dial Transplant. 1990; 5: 874-877.
8. Llach F, Yudd M. Pathogenic, clinical and therapeutic aspects of secondary hyperparathyroidism in chronic renal failure. Am J Kidney Dis. 1998; 32: S3-S12.
9. Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int. 1998; 53: 1399-1404.
10. Nolan C, Qunibi W. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. Kidney Int. 2005; 67 (Suppl 95): S13-S20.
11. Malberti F, Surian M, Poggio F, Minoia C, Salvadeo A. Efficacy and safety of long-term treatment with calcium carbonate as a phosphate binder. Am J Kidney Dis. 1988; 6: 487-491.
12. Argiles A, Kerr P, Canaud B, Flavier J, Mion C. Calcium kinetics and the long term effects of lowering dialysate calcium concentration. Kidney Int. 1993; 43: 630-640.
13. Fernandez E, Borras M, Pais B, Montoliu J. Low-calcium dialysate stimulates parathormone secretion and its long-term use worsens secondary hyperparathyroidism. J Am Soc Nephrol. 1995; 6: 132-135.
14. Argiles A, Mion C. Low-calcium dialysate worsens secondary hyperparathyroidism. J Am Soc Nephrol. 1996; 7: 635-636.
15. Sherman RA. On lowering dialysate calcium. Semin Dial. 1988; 1: 78-79.
16. Chertow G, Burke S, Paolo R. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245-252.
17. Taji Y, Morimoto T, Fukuhara S, Fukui T, Kuwahara T. Effects of low dialysate calcium concentration on health-related quality of life in hemodialysis patients. Clin Exp Nephrol. 2005; 9: 153-157.
18. Malberti F, Ravani P. The choice of the dialysate calcium concentration in the management of patients on hemodialysis and haemofiltration. Nephrol Dial Transplant. 2003; 18 (Suppl 7): 37-40.
19. Young E, Albert J, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: The dialysis outcomes and practice patterns study. Kidney Int. 2005; 67: 1179-1187.
20. Locatelli F, Cannata-Andia J, Drueke T. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant. 2002; 17: 723-731.
21. Young E, Albert J, Akizawa T, et al. Sevelamer vs calcium-containing phosphate binders and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol. 2005; 16: 47A.
22. Binswanger U. Calcium flux during hemodialysis. Semin Dial. 1990; 1: 1-2.
23. Argiles A, Mourad G. How do we have to use the calcium in the dialysate to optimize the management of secondary hyperparathyroidism. Nephrol Dial Transplant. 1998; 13 (Suppl 3): 62-64.
24. Malberti F, Surian M, Minetti L. Dialysate calcium concentration decrease exacerbates secondary hyperparathyroidism in dialysis patients given calcium carbonate as a phosphate binder. J Nephrol. 1991; 2: 75-81.
25. Fabrizi F, Bacchini G, Di Filippo S, Pontoriero G, Locatelli F. Intradialytic calcium balances with different calcium dialysate levels. Nephron. 1996; 72: 530-535.
26. Ermakova I, Novikov A, Pronchenko I. Use of the equipment for hemodialysis in the diagnosis of calcium metabolism disorders in terminal chronic renal failure. Med Tekh. 1991; 1: 27-29.
27. Ulozas E, Chebrolu S, Shanaah A, Daoud T, Leehey D, Ing T. Symptomatic hypocalcemia due to the inadvertent use of a calcium-free hemodialysate. Artif Organs. 2004; 28: 229-231.
28. Maynard J, Cruz C, Kleerekoper M, Levin N. Blood pressure response to changes in serum ionized calcium during hemodialysis. Ann Intern Med. 1986; 104: 358-361.
29. van Kuijk W, Mulder A, Peels C, Harff G, Leunissen K. Influence of changes in ionized calcium on cardiovascular reactivity during hemodialysis. Clin Nephrol. 1997; 47: 190-196.
30. van der Sande F, Cheriex E, van Kuijk W, Leunissen K. Effect of dialysate calcium concentrations on intra-dialytic blood pressure course in cardiac-compromised patients. Am J Kidney Dis. 1998; 32: 125-131.
31. Locatelli F, Covic A, Chazot C, Leunissen K, Luño J, Yaqoob M. Optimal composition of the dialysate, with emphasis on its influence on blood pressure. Nephrol Dial Transplant. 2004; 19: 785-796.
32. The National Institute of Diabetes and Digestive and Kidney Diseases. US Renal Data System USRDS 1999 Annual Report. Bethesda, MD: The National Institute of Diabetes and Digestive and Kidney Diseases; 1999.
33. Foley R, Parfrey P, Samak M. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis. 1998; 32 (Suppl 3): S112-S119.
34. Block G, Hulbert-Shearon T, Levin N, Port F. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998; 31: 607-617.
35. Giachelli C. Vascular calcification mechanisms. J Am Soc Nephrol. 2004; 15: 2959-2964.
36. Moe S, Chen N. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004; 95: 560-567.
37. Goldsmith D, Ritz E, Covic A. Vascular calcification: A stiff challenge for the nephrologist. Kidney Int. 2006; 66: 1315-1333.
38. Klemmer P. Calcium loading, calcium accumulation, and associated cardiovascular risks in dialysis patients. Blood Purif. 2005; 23 (Suppl 1): 12-19.
39. Tetta C, Gallieni M, Panichi V, Brancaccio D. Vascular calcifications as a footprint of increased calcium load and chronic inflammation in uremic patients: A need for a neutral calcium balance during hemodialysis? Int J Artif Organs. 2002; 25: 18-26.
40. Haydar A, Covic A, Colhoun H, Rubens M, Goldsmith D. Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int. 2004; 65: 1790-1794.
41. Kondos G, Hoff J, Serukov A, et al. Electron-beam tomography coronary artery calcium and cardiac events: A 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation. 2003; 107: 2571-2576.
42. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft F. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996; 27: 394-401.
43. Goodman W, Goldin J, Kuizon B, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000; 342: 1478-1483.
44. Matsuoka M, Iseki K, Tamashiro M, et al. Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol. 2004; 8: 54-58.
45. London G, Guerin A, Marchais S, Métivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003; 18: 1731-1740.
46. Blacher J, Guerin A, Pannier B, Marchais S, London G. Arterial calcification, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001; 38: 938-942.
47. Yoo S, Oh D, Yu S. The effects of low calcium dialysate on arterial compliance and vasoactive substances in patients with hemodialysis. Korean J Intern Med. 2004; 19: 27-32.
48. Morrison G, Michelson EL, Brown S, Morganroth J. Mechanism and prevention of cardiac arrhythmias in chronic hemodialysis patients. Kidney Int. 1998; 17: 811-819.
49. Nappi SE, Virtanen VK, Saha HH, Mustonen JT, Pasternack AI. QTc dispersion increases during hemodialysis with low-calcium dialysate. Kidney Int. 2000; 57: 2117-2122.
50. Sherman R, Bialy G, Gazinski B, Bernholc A, Eisinger R. The effect of dialysate calcium levels on blood pressure during hemodialysis. Am J Kidney Dis. 1986; 8: 244-247.
51. Henrich W, Hunt J, Nixon J. Increased ionized calcium and left ventricular contractility during hemodialysis. N Engl J Med. 1984; 310: 19-23.
52. Lang R, Fellner S, Neumann A, Bushinsky D, Borow K. Left ventricular contractility varies directly with blood ionized calcium. Ann Intern Med. 1988; 108: 524-529.
53. Kyriazis J, Kalogeropoulou K, Bilirakis L, et al. Dialysate magnesium level and blood pressure. Kidney Int. 2004; 66: 1221-1231.
54. Fellner S, Lang R, Neumann A, Spencer K, Bushinsky D, Borow K. Physiological mechanisms for calcium-induced changes in systemic arterial pressure in stable dialysis patients. Hypertension. 1989; 13: 213-218.
55. Ie E, Vletter W, ten Cate F, Weimar W, Zietse R. Increase in serum ionized calcium during diffusive dialysis does not affect left ventricular diastolic function. Blood Purif. 2004; 22: 469-472.
56. Malluche H, Mawad H, Monier-Faugere M. The importance of bone health in end-stage renal disease: Out of the frying pan, into the fire? Nephrol Dial Transplant. 2004; 19 (Suppl 1): 1-13.
57. Fiedler R, Deuber H, Langer T, Osten B, Mohan S, Jehle P. Effects of reduced dialysate calcium on calcium-phosphorus product and bone metabolism in hemodialysis patients. Nephron Clin Pract. 2004; 96: C3-c9.
58. Hamano T, Oseto S, Fujii N, et al. Impact of lowering dialysate calcium concentration on serum bone turnover markers in hemodialysis patients. Bone. 2005; 36: 909-916.
59. Kyriazis J, Glotsos J, Bilirakis L, et al. Dialysate calcium profiling during hemodialysis: Use and clinical implications. Kidney Int. 2002; 61: 276-287.
60. Pierratos A. Nocturnal home hemodialysis: An update on a 5-year experience. Nephrol Dial Transplant. 1999; 14: 2835-2840.
61. Al-Hejaili F, Kortas C, Leitch R, et al. Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. J Am Soc Nephrol. 2003; 14: 2322-2328.
62. Lindsay R, Alhejaili F, Nesrallah G, et al. Calcium and phosphate balance with quotidian hemodialysis. Am J Kid Dis. 2003; 42: S24-S29.
63. Chan C, Murali K, Ilumin M, Richardson R. Improvements in phosphate control with short daily in-center hemodialysis (SDHD). J Am Soc Nephrol. 2002; 12: 262A.
64. Lugon JR, Andre MB, Duarte ME, Rembold SM, Cruz E. Effects of in-center daily hemodialysis upon mineral metabolism and bone disease in end-stage renal disease patients. Sao Paulo Med J. 2001; 119: 105-109.
65. Toussaint N, Boddington J, Simmonds R, Waldron C, Somerville C, Agar J. Calcium phosphate metabolism and bone mineral density with nocturnal hemodialysis. Hemodial Int. 2006; 10: 280-286.
66. Walsh M, Culleton B, Tonelli M, Manns B. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int. 2005; 67: 1500-1508.
67. Veys N, Van Biesen W, Vanholder R, Lamiere N. The effects of long nocturnal dialysis on calcium, phosphate and bone status. Hemodial Int. 2003; 7: 83.
68. Sadek T, Mazouz H, Bahloul H, et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: An open-label, randomized study. Nephrol Dial Transplant. 2003; 18: 582-589.
69. Suki W, Zabaneh R, Cangiano J, et al. The DCOR Trial - A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients. J Am Soc Nephrol. 2005; 16 (abstract presented, ASN poster 745).
70. Backenroth R. Dialysate calcium use in hemodialysis patients. Kidney Int. 2003; 64: 1533.
71. Izumi M, Shirai K, Ito K, et al. Is 2.5mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines. Ther Aher Dial. 2005; 9: 24-31.
72. Ando R, Naito S, Inagaki Y, et al. The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin D metabolites. Ther Apher Dial. 2005; 9: 16-23.
73. Locatelli F, D'Amico M. Lanthanum carbonate. Curr Opinion Cardiov Pulm Renal Invest Drugs. 2000; 2: 372-377.
74. Schroeder N, Cunningham J. What's new in vitamin D for the nephrologists? Nephrol Dial Transplant. 2000; 15: 460-466.
75. Teng M, Wolf M, Lowrie E. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003; 349: 446-456.
76. Szczech L. The impact of calcimimetic agents on the use of different classes of phosphate binders: Results of recent clinical trials. Kidney Int. 2004; (Suppl 90): S46-S48.
77. Touam M, Menoyo V, Attaf D, Thebaud H, Drüeke T. High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe secondary hyperparathyroidism. Kidney Int. 2005; 67: 2065.
78. Cunningham J. Calcium concentration in the dialysate and calcium supplements. Nephrol Dial Transplant. 2000; 15 (Suppl 5): 34-35.